AbCellera BiologicsABCL +10.81%59 PS Ratio is 27.95 as of Jun. 27, 2026, which is 42% above its 10-year median of 19.64. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 936 Biotechnology companies, AbCellera Biologics ranks worse than 70.83% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, AbCellera Biologics's share price is $7.38.
AbCellera Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.26. Hence, AbCellera Biologics's PS Ratio for today is 27.95.
The historical rank and industry rank for AbCellera Biologics's PS Ratio or its related term are showing as below:
ABCL'
s PS Ratio Range Over the Past 10 Years
Min: 4.52 Med: 19.64 Max: 512.17
Current: 27.95
During the past 8 years, AbCellera Biologics's highest PS Ratio was 512.17. The lowest was 4.52. And the median was 19.64.
ABCL's PS Ratio is ranked worse than 70.83% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs ABCL: 27.95
AbCellera Biologics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of AbCellera Biologics was 238.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -45.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -37.10% per year.
During the past 8 years, AbCellera Biologics's highest 3-Year average Revenue per Share Growth Rate was 217.00% per year. The lowest was -56.40% per year. And the median was -45.30% per year.
Back to Basics: PS Ratio
AbCellera Biologics (NAS:ABCL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
AbCellera Biologics PS Ratio Related Terms
AbCellera Biologics PS Ratio Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AbCellera Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's PS Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
AbCellera Biologics's Share Price of today is $7.38. AbCellera Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
AbCellera Biologics (ABCL) has a PS Ratio of 27.95 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on AbCellera Biologics and its competitors. This is 42% above median its historical median of 19.64. Over the past decade, AbCellera Biologics' PS Ratio has ranged from 4.52 to 512.17. According to the industry distribution chart, AbCellera Biologics ranks #663 out of 936 companies in the Biotechnology industry, placing it in the top 70.8%.
Is AbCellera Biologics' PS Ratio too high?
AbCellera Biologics' current PS Ratio of 27.95 is 42% above median its 10-year median of 19.64. Over the past 10 years, this metric has ranged from a low of 4.52 to a high of 512.17. The Biotechnology industry median PS Ratio is 9.17. AbCellera Biologics' value of 27.95 is 205% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #663 out of 936 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' PS Ratio compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #663 out of 936 companies for PS Ratio. This places AbCellera Biologics in the lower half of its industry. The industry median PS Ratio is 9.17. AbCellera Biologics' value of 27.95 is 205% above this benchmark. Historically, AbCellera Biologics' own PS Ratio has ranged from 4.52 to 512.17 over the past decade. While the company's 10-year median is 19.64 vs. the industry median of 9.17, AbCellera Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current PS Ratio of 27.95 is 205% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current PS Ratio is 27.95, which is 42% above median its own 10-year median of 19.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current PS Ratio is 27.95, which is 42% above median its 10-year median of 19.64 and 205% above the Biotechnology industry median of 9.17. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current PS Ratio is 27.95 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
PS Ratio: 27.95 (42% above median its 10-year median of 19.64)
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
Industry Position: 205% above the Biotechnology median (#663 of 936)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
